Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

April 25, 2023

https://www.globenewswire.com/news-release/2023/04/25/2653800/0/en/Lyra-Therapeutics-Announces-Restart-of-Pivotal-Phase-3-ENLIGHTEN-II-Clinical-Trial-of-LYR-210-in-Chronic-Rhinosinusitis.html

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq:LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that it has resumed screening and enrollment in ENLIGHTEN II, its second pivotal Phase 3 clinical trial of LYR-210 in patients with CRS. LYR-210 is a bioresorbable nasal implant designed as an alternative to sinus surgery for the millions of CRS patients who remain symptomatic despite treatment.

Read more at globenewswire.com

Related news for (LYRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.